- Home
- SABR vs SLS Comparison
SABR vs SLS Comparison
Compare SABR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | SLS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.0M | 706.7M |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SABR | SLS |
|---|---|---|
| Price | $1.59 | $5.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.70 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 15.3M | 5.9M |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 62.69 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,866,956,000.00 | N/A |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $3.26 | N/A |
| P/E Ratio | $1.27 | ★ N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $0.95 |
| 52 Week High | $3.63 | $6.14 |
Technical Indicators
Market Signals| Indicator | SABR | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 54.66 |
| Support Level | $1.20 | $1.48 |
| Resistance Level | $1.70 | $6.14 |
| Average True Range (ATR) | 0.21 | 0.53 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 62.84 | 41.91 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.